title: The association of HPV-16 seropositivity and natural immunity to reinfection: insights from compartmental models.
abstract: BACKGROUND
  Seroreactivity, processes of seroconversion and seroreversion, in the context of HPV infection has been investigated in numerous studies. However, the data resulting from these studies are usually not accounted for in mathematical transmission models of various HPV types due to gaps in our understanding of the nature of seroreactivity and its implications for HPV natural history.
  
  
  METHODS
  In this study we selected a number of simple but plausible compartmental transmission models of HPV-16, differing in assumptions regarding the relation between seropositivity and immunity, and attempted to calibrate them to Australian HPV seroprevalence data for females and males, as well as DNA prevalence data for females, using a Bayesian model comparison procedure. We ranked the models according to both their simplicity and ability to be fitted to the data.
  
  
  RESULTS
  Our results demonstrate that models with seroreversion where seropositivity indicates only a partial or very short-term full protection against re-infection generate age-specific HPV DNA prevalence most consistent with the observed data when compared with other models.
  
  
  CONCLUSIONS
  Models supporting the notion that seropositive individuals are fully immune to reinfection demonstrated consistently inferior fits to the data than other models making no such assumption.
authors: The Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia. ikorostil@kirby.unsw.edu.au
authors: Igor A
authors: IA
authors: Korostil
authors: Suzanne M
authors: SM
authors: Garland
authors: Matthew G
authors: MG
authors: Law
authors: David G
authors: DG
authors: Regan
mesh_terms: D001499:Bayes Theorem; D005260:Female; D052162:Human papillomavirus 16 / Q000276:immunology*; D006801:Humans; D008297:Male; D018448:Models, Immunological; D030361:Papillomavirus Infections / Q000276:immunology* / Q000635:transmission / Q000821:virology*; D016036:Seroepidemiologic Studies
references: Br J Cancer. 2004 Oct 4;91(7):1269-74
references: 15292929
references: Bull Math Biol. 2008 Nov;70(8):2126-76
references: 18841421
references: Emerg Infect Dis. 2007 Jan;13(1):28-41
references: 17370513
references: J Gen Virol. 2009 Jun;90(Pt 6):1515-1526
references: 19264653
references: Sex Transm Dis. 1995 Jul-Aug;22(4):236-43
references: 7482107
references: Cancer Epidemiol Biomarkers Prev. 2003 Jun;12(6):485-90
references: 12814991
references: J Infect Dis. 2004 Nov 1;190(9):1563-74
references: 15478060
references: J Infect Dis. 2000 Jun;181(6):1911-9
references: 10837170
references: Br J Cancer. 2003 Jan 13;88(1):63-73
references: 12556961
references: Stat Med. 2013 May 20;32(11):1917-53
references: 22961869
references: J Infect Dis. 2002 Aug 15;186(4):462-9
references: 12195372
references: PLoS Med. 2006 May;3(5):e138
references: 16573364
references: J Infect Dis. 2008 May 15;197(10):1436-47
references: 18419547
references: Am J Epidemiol. 2006 Mar 15;163(6):534-43
references: 16421235
references: Cancer Res. 2012 Feb 1;72(3):676-85
references: 22123925
references: J Infect Dis. 2008 Sep 15;198(6):827-35
references: 18657037
references: BMC Med. 2011 Sep 13;9:104
references: 21910918
references: Aust N Z J Public Health. 2003;27(2):106-17
references: 14696700
references: Epidemics. 2010 Mar;2(1):21-8
references: 21352773
references: Am J Epidemiol. 2010 Apr 1;171(7):817-25
references: 20231211
references: J Infect Dis. 2011 Jul 15;204(2):209-16
references: 21673030
references: Emerg Infect Dis. 2008 Jun;14(6):888-94
references: 18507898
references: N Engl J Med. 2003 Feb 6;348(6):518-27
references: 12571259
references: IMA J Math Appl Med Biol. 1994;11(3):161-92
references: 7822888
references: Int J Cancer. 2011 Feb 15;128(4):927-35
references: 20473886
references: Epidemiology. 2002 Nov;13(6):631-9
references: 12410003
references: Br J Cancer. 2006 Jul 3;95(1):56-61
references: 16773068
references: J Infect Dis. 2011 Jul 1;204(1):94-102
references: 21628663
references: Br J Cancer. 2007 Nov 5;97(9):1322-8
references: 17923869
references: J Infect Dis. 2011 Dec 1;204(11):1723-9
references: 21984739
references: Cancer Epidemiol Biomarkers Prev. 1997 Apr;6(4):233-7
references: 9107427
references: Vaccine. 2010 May 28;28(24):4091-102
references: 19909831
references: Lancet. 2011 Mar 12;377(9769):932-40
references: 21367446
references: Clin Infect Dis. 2008 Jun 1;46(11):1647-55
references: 18444790
references: Sex Transm Dis. 2000 Nov;27(10):600-9
references: 11099075
references: J Infect Dis. 2002 Sep 15;186(6):737-42
references: 12198606
references: J Natl Cancer Inst. 2010 Nov 3;102(21):1653-62
references: 20944077
references: Sex Health. 2007 Sep;4(3):147-63
references: 17931528